Osimertinib’s Proton-Catalyzed, Pseudoconcerted EGFR Inhibition Guides Next-Generation Inhibitor Design

Third-generation inhibitors such as osimertinib irreversibly inhibit the epidermal growth factor receptor tyrosine kinase (EGFR-TK) via Michael addition to Cys797, yet the mechanism of covalent bond formation remains unsettled. Here, density functional theory-level quantum mechanics/molecular mechanics (QM/MM) computations delineate a proton-catalyzed, pseudoconcerted mechanism for covalent inhibition of EGFR by osimertinib. The computed Gibbs energy profile features a single transition state (TS1) in which Cys797 deprotonation, nucleophilic attack at osimertinib’s Michael acceptor, and protonation of the acceptor’s carbonyl oxygen by osimertinib’s terminal aliphatic aminium occur simultaneously, in contrast to previous stepwise proposals. Natural bond orbital (NBO) analysis shows that carbonyl O-protonation attenuates carbonyl π bonding, increases β-carbon (Cβ) electrophilicity, and thereby facilitates formation of the Cys797–Cβ bond. The resulting path proves to be more favorable in both kinetics and thermodynamics than stepwise alternatives, consistent with experimental trends. The calculations also rationalize osimertinib’s preferential inhibition of the T790M mutant. Electrostatic potential (ESP) analysis demonstrates that T790M subtly redistributes charge within osimertinib’s pyrimidine–indole scaffold, enhancing the cationic character at the indole N-methyl substituent and strengthening its electrostatic interaction with Asp855 to stabilize the reactant complex. Together, these results provide a mechanistic framework for covalent bond formation underlying EGFR inhibitionhighlighting inhibitor-derived proton catalysis and Asp855 engagementand offer design principles for next-generation covalent inhibitors with improved potency and resistance-breaking potential.